The Welsh Government has agreed a deal with Vertex Pharmaceuticals to give access to the triple combination therapy, Kaftrio, to people with cystic fibrosis (CF) living in Wales on the day the drug receives its European licence.
Following a major step forward in access to Kaftrio, a genotype-specific treatment for cystic fibrosis (CF), the Cystic Fibrosis Trust’s Director of Policy, Programmes, and Support, Dr Keith Brownlee, sets out the Trust’s determination to ensure the best care, treatment and support for everyone with cystic fibrosis.
This week is Co-production Week in the UK. Here, Tracy Turc-Milloy, Clinical Quality Improvement Manager, explains the concept of co-production and how we are working to put people with cystic fibrosis (CF) at the centre of decisions about our projects and strategies.
Our Youth Advisory Group (YAG) believe it’s important to celebrate the amazing things young people with cystic fibrosis (CF) can do. They are calling on children and young people with CF to share their passions and creative pieces for their latest project ‘More than CF’. Here, YAG member Nicola shares her own creation and explains how you can get involved.
NHS England has announced a deal for access to the life-saving drug Kaftrio (called ‘Trikafta’ in the US) on the day it receives its European licence, bringing hope to thousands across the UK.
